Search results for: Kenneth Arrow
Filter search results
OHE Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
14 June 2017, 11:00pm
…Studies. She has been awarded the Kenneth J. Arrow Prize in Health Economics from the International Health Economics Association, for her work on the links between economic status and health…
Invitation to OHE’s Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
12 May 2017
…Studies. She has been awarded the Kenneth J. Arrow Prize in Health Economics from the International Health Economics Association, for her work on the links between economic status and health…
Economic Aspects of Non-Hodgkin’s Lymphoma
1 July 1998
…they are all cancerous growths of lymphocytes. These are cells of the immune system which are produced from bone marrow and are located within the lymph glands. Lymphocytes are designed…
OHE Lunchtime Seminar: Management in the NHS
4 September 2017, 11:00pm
…Reenan were awarded the International Health Economics Association Arrow Award for the best paper in health economics worldwide for their paper “Can Pay Regulation Kill?” JPE 118(21):222-273. In 2016 Carol…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
…criteria should not deviate from the FDA label in a manner that would narrow coverage. (3) For drugs deemed to be priced unreasonably, criteria may narrow coverage to the eligibility…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…the 2018 level of 59 is almost double that. FIGURE 1: ANNUAL NUMBERS OF NMES AND BLAS APPROVED BY FDA’S CDER Source: https://media.nature.com/original/magazine-assets/d41573-021-00002-0/d41573-021-00002-0.pdf 3. CBO relies on a narrow conception…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…FDA label in a manner that would narrow coverage. (3) For drugs deemed to be priced unreasonably, criteria may narrow coverage to the eligibility criteria from the pivotal trials if…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Share this: Download publication Matthew Napier Brittany Darrow Matthias Hofer Mikel Berdud Amanda Cole Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting…
Benchmarking and Incentives in the NHS
5 January 2000
…total effort. Successful agencies pursue narrow and clear missions. This suggests a limited number of benchmarks should be set for each type of organisation within the NHS, with different benchmarks…